|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001758,
umls-concept:C0002199,
umls-concept:C0042749,
umls-concept:C0439230,
umls-concept:C0449297,
umls-concept:C0524910,
umls-concept:C0871261,
umls-concept:C1521828,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1994-3-2
|
|
pubmed:abstractText |
To evaluate the effect of prolonged interferon-alpha treatment on serum aminotransferase levels and hepatitis C virus RNA in serum, 40 patients with chronic hepatitis C virus infection were treated with 3 MU interferon-alpha 2b thrice weekly for 60 wk. Before treatment all patients had elevated serum ALT levels for at least 1 yr, antibodies to HCV by second-generation tests and liver histological findings consistent with chronic hepatitis C. Before treatment hepatitis C virus RNA was found in serum in 39 of 40 (97.5%) patients. Normalization of ALT levels at treatment cessation was seen in 24 of 40 (60%) patients, of whom 15 of 24 (62.5%) had sustained ALT responses up to 24 wk after treatment. At follow-up, 24 wk after treatment, hepatitis C virus RNA was cleared from serum in 17 of 40 (42.5%) patients, including all sustained responders, one nonsustained responder and one nonresponder. We conclude that 60 wk of treatment with interferon-alpha 2b seems to induce a high percentage of sustained response, which coincides with cessation of viral replication.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0270-9139
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
280-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7507462-Adult,
pubmed-meshheading:7507462-Aged,
pubmed-meshheading:7507462-Alanine Transaminase,
pubmed-meshheading:7507462-Chronic Disease,
pubmed-meshheading:7507462-Drug Administration Schedule,
pubmed-meshheading:7507462-Female,
pubmed-meshheading:7507462-Follow-Up Studies,
pubmed-meshheading:7507462-Hepacivirus,
pubmed-meshheading:7507462-Hepatitis Antibodies,
pubmed-meshheading:7507462-Hepatitis C,
pubmed-meshheading:7507462-Hepatitis C Antibodies,
pubmed-meshheading:7507462-Humans,
pubmed-meshheading:7507462-Immunoblotting,
pubmed-meshheading:7507462-Interferon-alpha,
pubmed-meshheading:7507462-Male,
pubmed-meshheading:7507462-Middle Aged,
pubmed-meshheading:7507462-RNA, Viral,
pubmed-meshheading:7507462-Recombinant Proteins,
pubmed-meshheading:7507462-Time Factors,
pubmed-meshheading:7507462-Treatment Outcome,
pubmed-meshheading:7507462-Viremia
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks.
|
|
pubmed:affiliation |
Department of Infectious Diseases, Karolinska Institute, Danderyds Hospital, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
